Effects of Phthalates on Androgen Receptor Regulation Associated with Castration-Resistant Prostate Cancer Development
Technical Report,30 Jun 2017,29 Jun 2018
University of Wisconsin System MADISON United States
Pagination or Media Count:
Prostate cancer is one of the leading causes of death for men in the United States. Initially, prostate cancer patients are treated with androgen deprivation therapy. This treatment is usually successful at first however, prostate cancer can recur years later as castration resistant prostate cancer CRPC. CRPC is much more aggressive and is frequently lethal. Despite the immense clinical significance of CRPC, little is known about the molecular mechanisms that cause prostate cancer to become castration-resistant. We have found that the RNA helicase DDX3 plays a critical role in translational control of the androgen receptor AR in CRPC, highlighting a new mechanism by which prostate cancer becomes castration resistant. Future efforts will be dedicated to determining if DDX3-dependent translational control plays a role in phthalate-triggered reduction of AR in prostate cancer.
- Medicine and Medical Research